Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2005

View Archived Issues

Sigma1 receptor agonists demonstrate neuroprotection in vitro

Subcutaneous and buccal spray insulin induce similar effects in patients with type 1 diabetes

First evidence for oncostatin M neuroprotection

Capsazepine potentiates epithelial Na+ channel delta currents

Efficacy and safety data for otamixaban from preclinical studies

New SPA agreement for Altropane

Combination of microbicides CAP and UC-781 synergistically inhibits HIV-1 replication

WHI-07 alone or in combination with vanadocene protects cats from FIV

Nektar to acquire Aerogen

Progress in extended collaboration between Karo Bio and Wyeth

Aastrom receives SBIR grant extending adult stem cell process to other tissues

Debiopharm and DeveloGen partner of PTR-262 for myasthenia gravis

Ascentia Biomedical enters option agreement with U. of Washington

New anti-HCV agents prepared and tested

Novel agents for respiratory disorders claimed in recent patents

New agents for arthritis, inflammatory disorders, etc., in early development

MD-0727 reduces liver cholesterol accumulation in hamsters by more than 90%

Beneficial action of ONO-2921 against neuropathic pain in rats reported

Enrollment opens in phase II/III study of Troxatyl for AML

Orphan drug designation for AS-1411 for renal cancer

sBLA filing for Rituxan

Canadian clearance for phase I/II study of nimotuzumab in NSCLC

FDA denies Public Citizen's petition against Meridia

Oral contraceptive Yasminelle approved in Netherlands

Thelin MAA accepted for review

Serono inlicenses worldwide rights to Genmab's HuMax-CD4

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026